Piero Periti Review Article Award 2013 The Editors of the Journal of Chemotherapy have instituted an annual award in the memory of Professor Piero Periti (see photo), founder of the Journal, for the best Review Article published during the year in the Journal.

Review

Carbapenems Dominique Breilh1, Jeannette Texier-Maugein2, Bernard Allaouchiche3, Marie-Claude Saux1, Emmanuel Boselli1,3 1

Laboratory of Clinical Pharmacokinetics and Clinical Pharmacy, INSERM U1034, Haut-Le´veˆque hospital, CHU Bordeaux, University of Bordeaux, Segalen, Pessac, France, 2Bacteriology, Haut-Le´veˆque hospital, CHU Bordeaux, University of Bordeaux, Segalen, Pessac, France, 3Department of Anesthesiology and Intensive Care, E´douard Herriot hospital, HCL, University of Lyon, Lyon, France Objective: To assess the relative strengths and weaknesses of carbapenems by considering their microbiological, clinical, pharmacokinetics and pharmacokinetic/pharmacodynamic (PK/PD) properties and defining optimal conditions of uses of the new generation of carbapenems. Methods: Literature review. Results: Except for ertapenem, the spectrum of activity is similar for all carbapenems, with little differences in activities of individual agents. The absence or reduced expression of two major porins in combination with various beta-lactamases and alteration of some penicillin binding proteins have been implicated in carbapenem resistance. All carbapenems are not alike, although they have very similar pharmacokinetic properties. The most important PK/PD parameter predicting bacteriological and clinical efficacy is T>MIC. There is some circumstantial evidence, such as clinical data in severe critically ill septic patients, impaired renal function patients and neutropenic patients that imipenem has to exceed 66% of T>MIC to result in good clinical outcome. Continuous or extend infusion of carbapenems should result in at least equal efficacy to that of intermittent infusion in the treatment of infections with susceptible bacteria and appear highly appropriate for use in critically ill patients. Conclusions: Maximizing clinical outcomes and minimizing antibiotic resistance using individualized doses may be best achieved with therapeutic drug monitoring of carbapenems.

The winner of the award in 2013 is Dominique Breilh of the University of Bordeaux, Segalen, Pessac, France (see photo), for her article entitled ‘‘Carbapenems’’ published in our February, 2013 issue. Dominique Breilh’s article will be available free of charge on our Journal’s website: www.maneyonline.com/loi/joc. We congratulate her on her fine article. The abstract of her paper is above. The article can be found on our website (www.maneyonline.com/loi/joc)

ß 2014 Edizioni Scientifiche per l’Informazione su Farmaci e Terapia DOI 10.1179/1120009X14Z.000000000222

Journal of Chemotherapy

2014

VOL .

26

NO .

3

129

Piero Periti review article award 2013.

Piero Periti review article award 2013. - PDF Download Free
59KB Sizes 2 Downloads 3 Views